



## **PRESS RELEASE**

### **Antitope Announces Research Collaboration with Ablynx**

25 August 2010 - Antitope Ltd. of Cambridge UK ("Antitope") today announced a research collaboration with Ablynx NV of Ghent, Belgium ("Ablynx") whereby Antitope will apply its proprietary EpiScreen™ technology to profile a series of Nanobodies® developed by Ablynx for possible T cell epitopes.

"We are delighted to be working with Ablynx whose Nanobody-based therapeutic research programmes represent exciting new opportunities in a range of major disease areas" said Dr Matthew Baker, Chief Scientific Officer and co-founder of Antitope, adding, "We look forward to applying the EpiScreen™ technology to enable Ablynx to select Nanobodies with the lowest potential for immunogenicity."

Dr Hilde Revets, Senior Research Fellow of Ablynx added: "We are looking forward to our collaboration with Antitope. This study will help to further characterise our Nanobody platform."

#### **About Antitope**

Antitope Ltd. is a privately-held Cambridge UK-based biotechnology company specialising in immunogenicity testing and the engineering of therapeutic antibodies/proteins with reduced immunogenicity. Antitope's proprietary EpiScreen™ technology provides for preclinical analysis of the immunogenicity potential of therapeutic antibodies and proteins. Antitope's proprietary Composite Human Antibody™ technology results in humanised antibodies devoid of T cell epitopes. Antitope has established multiple commercial relationships with leading biotechnology and pharmaceutical companies worldwide.

For further information on Antitope visit;  
<http://www.antitope.co.uk> or contact:  
Dr. Neil Butt  
Business Development Director, Antitope Ltd.  
Tel: +44 (0)1223 496190

Nanobody is a registered trademark of Ablynx NV